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Poster Session II S293Conclusion: This novel regimen is safe. There were no regimen-
related deaths in this high-risk pt population. All evaluable pts
achieved a CR. Engraftment in recipients of CB transplants was
rapid. This regimen demonstrates promising anti-leukemic effects.
Chemotherapy alone regimens can provide a safe and effective con-
trol of disease, and also demonstrate that TBI is not necessary to en-
sure engraftment in CB recipients. This protocol warrants further
investigation.366
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Allogeneic hematopoietic stem cell transplantation (alloHCT)
is a curative treatment option for myelofibrosis. Reduced-toxicity
conditioning regimens have been utilized and reported to be fea-
sible. We report a series of 18 patients with myelofibrosis who
underwent alloHCT with either reduced-toxicity or myeloabla-
tive regimens from 2000 to 2008. Ten (56%) were male and
median age at allograft was 55.5 (range 23-63) years. Seven
(39%) had Dupriez score of 1 (intermediate-risk) and 11
(61%) had the score of 2 (high-risk). Reduced-toxicity regimen
consisted of pharmacokinetic-targeted IV busulfan plus fludara-
bine [t-IV Bu/Flu] (n5 14) or fludarabine plus melphalan
[Flu/Mel] (n5 1). Myeloablative conditioning included busulfan
plus cyclophosphamide [Bu/Cy] (n5 2) or cyclophosphamide
plus total body irradiation [Cy/TBI] (n5 1). Graft-versus-host
disease (GVHD) prophylaxis was either tacrolimus-based regi-
men (n5 15) or cyclosporine-based (n5 3). The graft sources
were from MRD5 9 (50%), MUD5 8 (44%), and MMUD5 1
(B Ag). Four (22%) pts received bone marrow grafts and other
14 cases were G-CSF-mobilized PBSC. Median CD34+ cell
dose was 9.93  106 cells/kg. Median days to ANC$ 500
cells/mL and PLAT$ 20,000/mL were 17 (range 15-28) days
and 18 (range 8-213) days, respectively. All patients with t-IV
Bu/Flu achieved platelet engraftment within 30 days. Median
donor bone marrow chimerisms by STR-PCR were 97.5 (range
91-100: n5 14) % on day 30, 99.5 (range 92-100: n5 12) % on
day 90, and 100 (range 67-100: n5 10) % on day 180. One pa-
tient with Flu/Mel conditioning received second infusion of cells
on day 89 due to graft failure. Acute GVHD (max grade)
were 0 (n5 7), 1 (n5 3), 2 (n5 4), and 3 (n5 4). Overall sur-
vival was 52.8% with a median follow-up of 14.5 months (range
3-62 months). Two patients who received myeloablative regi-
mens (Cy/TBI and Bu/Cy) developed interstitial pneumonitis
and diffuse alveolar hemorrhage. One patient progressed to
acute myeloid leukemia post transplant. The causes of non-re-
lapse mortality were infections (57%) and GVHD (43%). In
conclusion, t-IV Bu/Flu is a feasible regimen for the treatment
of myelofibrosis and it shows encouraging hematopoietic en-
graftment even in high-risk myelofibrosis.Chimerism at different time points
Median (range) %
Chimerism
by STR-PCR Day 30 Day 90 Day 180CD3 58.5 (44-100) 64.5 (45-100) 83.5 (37-100)
CD33 100 (100) 100 (100) 100 (45-100)
Unsorted BM 97.5 (91-100) 99.5 (92-100) 100 (67-100)367
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Despite standard CyA/MTX GvHD prophylaxis, severe acute
GVHD occurs after 35% of matched sibling HCT. MTX is asso-
ciated with mucositis, delayed engraftment and pulmonary toxicity.
Campath anti-CD52 antibody may reduce GvHD by targeting lym-
phocytes and dendritic cells. Studies with high doses (100 mg) of the
humanized Campath1H (alemtuzumab) revealed increased inci-
dence of relapse and severe viral infections. We report our single
centre experience of low dose (20-10 mg) alemtuzumab as GvHD
prophylaxis in 26 consecutive matched sibling (n5 12), related (1)
or unrelated transplantations (13) performed during 1/2007-6/
2009. Median pt age was 36y (17-59). Diagnoses were AML(15),
ALL(8), MDS-RAEB(1), T-NHL (1), PNH (1). 20 pts were trans-
planted in CR1 and 6 with advanced disease. Conditioning was
BuCy5 12, TBI/VP16/Cy5 5, Flu/BCNU/Melphalan(FB/M) or
FB + Thiotepa5 8,HDARA-C + FB/M5 1. All pts received periph-
eral blood stem cells. The first 11 pts received for GvHDprophylaxis
iv alemtuzumab 20 mg absolute (10 mg on d-2 and d-1), the next 5
pts received 15 mg (10 mg d-2, 5 mg d-1) and the last 10 pts received
total 10 mg alemtuzumab (5 mg on d-2 and d-1). All pts engrafted
promptly (WBC. 1000/ml on d + 14 (9-19), PLT. 50000/ml on
d + 12(7-19)) and revealed complete BM and PB chimerism on
d + 30, except one with refractory disease. Two patients who discon-
tinued CyA on d + 25 (incompliance) and d + 30 (refractory disease)
experienced steroid/ATG resistant, fatal GvHD. From the remain-
ing pts, none revealed gut or liver aGvHD, whereas 10pts (38.5%)
experienced steroid-sensible skin GvHD St I-II between d + 12-
d + 57 (median d + 17). 16 pts revealed CMV reactivation but no
CMV disease occurred. CyA could be discontinued in all evaluable
pts at median on d + 120 (25-210). 8 out of 20 evaluable pts (40%)
revealed mild skin chronic GvHD, 2 moderate skin cGvHD which
resolved with steroids and one extensive skin and liver GvHD. After
a median follow up of 323 days (24-902), 17/26 pts are alive (65.4%)
and in CR and 9 died (relapse n5 6, TRM n5 3). From the 6 pts
who died due to relapse, 4/6 were at advanced stage (.CR-1) at
transplant, 5/6 underwent sibling HCT and 5/6 received the higher
(20 mg) Campath dose. Median Karnofsky is 100% and only 1 pt re-
ceives steroids for skin cGvHD. In conclusion, in vivo low dose
Campath confers an efficient GvHD prophylaxis. Campath 10 mg
seems to be the optimal schedule for efficient GvHD prophylaxis
without compromising relapse in sibling and matched unrelated
HCT.368
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Double cord blood transplantation (DCBT) has been used in-
creasingly and has proven to be both safe and efficacious. In chime-
rism analysis, previous studies have[ indicated single unit
predominance early after DCBT. In the present study, we evaluated
the chimeric pattern in T-, B- and myeloid cells using PCR-based
chimerism analysis in seven patients after DCBT: five patients had
acute leukemia and two had lymphoma. Five patients received mye-
loablative conditioning and two patients were given reduced inten-
sity conditioning. All patients received antithymocyte globulin
(ATG) beforeDCBT.Three of the six evaluable patients showed do-
nor–donor mixed chimerism in all cell lineages at 90 days after
DCBT. Interestingly, two patients in long-term follow-up showed
mixed donor chimerism in all cell lineages at 25 and 35 months after
DCBT, respectively. Both patients are doing clinically well. Neither
of the two developed GVHD after DCBT. In conclusion, in this
study donor–donor mixed chimerism was common after high dose
ATG and DCBT. Further studies are warranted concerning the im-
munological consequences of the phenomenon of donor–donor
mixed chimerism after DCBT.
